AYVAKIT (avapritinib)

SELF-ADMINISTRATION

Indications for Prior Authorization:
  • Indicated for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations
Patients must meet the following criteria for the indication(s) above:
  • 18 years of age or older, AND
  • Prescribed by an oncologist, AND
  • Patient has a diagnosis of unresectable or metastatic GIST, AND
  • Patient has a PDGFRA exon 18 mutation, including PDGFRA D842V mutations, as confirmed by chart note documentation, AND
  • Patient has tried and failed Imatinib, AND
  • Coadministration of Ayvakit™ with strong and moderate CYP3A inhibitors or inducers should be avoided
Dosing:
  • 300 mg orally once daily until disease progression or unacceptable toxicity
  • If concomitant use with a moderate CYP3A inhibitor cannot be avoided, reduce the starting dose of Ayvakit™ from 300 mg orally once daily to 100 mg orally once daily
Approval:
  • 1 year

 

Last review date: May 19, 2020